Business Context and Reporting Period
Company: Trovagene, Inc. (Note: Input metadata referenced "Cardiff Oncology, Inc.", but the filing text identifies the registrant as Trovagene, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2020
Reporting Period: Single event date (January 21, 2020)
Business Context: The Company is a biopharmaceutical entity focused on oncology, specifically reporting on clinical trial data for metastatic KRAS-mutated colorectal cancer (mCRC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
There are no financial material changes reported in this document. The material event is the announcement of upcoming clinical data presentation.
Guidance, Outlook, and Management Commentary
- Clinical Update: The Company announced that a poster featuring safety and efficacy data from its Phase 1b/2 study in metastatic KRAS-mutated colorectal cancer (mCRC) will be presented.
- Event Details: The presentation is scheduled for Saturday, January 25, 2020, at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium in San Francisco.
- Exhibits: A press release dated January 21, 2020, is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific safety and efficacy data presented in the poster at the ASCO 2020 Gastrointestinal Cancers Symposium on January 25, 2020.
- Review the full text of the press release furnished as Exhibit 99.1 for detailed clinical trial results.
- Confirm the Company's ticker symbol (TROV) and listing status on the Nasdaq Capital Market.